Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byun, D.-S.
Right arrow Articles by Chi, S.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byun, D.-S.
Right arrow Articles by Chi, S.-G.
[Cancer Research 61, 7034-7038, October 1, 2001]
© 2001 American Association for Cancer Research


Advances in Brief

Frequent Epigenetic Inactivation of RASSF1A by Aberrant Promoter Hypermethylation in Human Gastric Adenocarcinoma1

Do-Sun Byun, Min-Goo Lee, Kwon-Seok Chae, Byung-Gyu Ryu and Sung-Gil Chi2

Department of Pathology, School of Medicine, Kyung Hee University, Seoul 130-701, Korea

Methylation associated inactivation of RASSF1, a putative tumor suppressor identified at 3p21.3, has been frequently observed in several human malignancies, including lung and breast cancers. To explore the penetrance of RASSF1 in gastric carcinogenesis, we performed expression and mutation analyses of 3 isotypes of RASSF1 (A, B, and C) in 150 gastric specimens, including 15 carcinoma cell lines. RASSF1A and RASSF1B transcripts were not expressed in 60% (9 of 15) and 33% (5 of 15) of gastric carcinoma cell lines, respectively, whereas RASSF1C was detectable in all cell lines. Bisulfite DNA sequencing analysis revealed that the CpG island in the RASSF1A promoter is hypermethylated in all RASSF1A-nonexpressing cell lines. In addition, both RASSF1A and RASSF1B were re-expressed by treatment with the demethylating agent 5-aza-2'-deoxycytidine. Among 90 primary gastric adenocarcinomas examined, 41 (46%) and 19 (21%) expressed no or abnormally low levels of RASSF1A and RASSF1B, respectively, and 12 (13%) tumors showed no expression of both isoforms. Loss or abnormal down-regulation of RASSF1A correlated with tumor stage and grade but not with histological types of tumors. Methylation-specific PCR analysis demonstrated that 95% (39 of 41) of RASSF1A-nonexpressing primary tumors are methylated at the CpG sites in the promoter, whereas none of the adjacent noncancerous or normal tissues are methylated. No somatic mutations were detected in RASSF1 transcripts expressed in unmethylated tumors. However, 10 methylated tumors, including 4 cell lines, showed low genomic levels of RASSF1 and expressed no RASSF1A transcripts, suggesting that RASSF1A inactivation might be caused by both epigenetic and genetic mechanisms in a subset of gastric adenocarcinomas. In conclusion, our data indicate that epigenetic transcriptional silencing of RASSF1, especially RASSF1A isoform, is a frequent event in gastric tumorigenesis and might play an important role in the malignant progression of gastric adenocarcinomas.




This article has been cited by other articles:


Home page
JCOHome page
M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al.
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J. Geli, N. Kiss, F. Lanner, T. Foukakis, N. Natalishvili, O. Larsson, P. Kogner, A. Hoog, G. J Clark, T. J Ekstrom, et al.
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma
Endocr. Relat. Cancer, March 1, 2007; 14(1): 125 - 134.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Pijnenborg, G. Dam-de Veen, N Kisters, B Delvoux, M van Engeland, J. Herman, and P. Groothuis
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer
Ann. Onc., March 1, 2007; 18(3): 491 - 497.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Zhang, N. Fatima, and M. L. Dufau
Coordinated Changes in DNA Methylation and Histone Modifications Regulate Silencing/Derepression of Luteinizing Hormone Receptor Gene Transcription
Mol. Cell. Biol., September 15, 2005; 25(18): 7929 - 7939.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. van der Weyden, K. K. Tachibana, M. A. Gonzalez, D. J. Adams, B. L. Ng, R. Petty, A. R. Venkitaraman, M. J. Arends, and A. Bradley
The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis
Mol. Cell. Biol., September 15, 2005; 25(18): 8356 - 8367.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Agathanggelou, W. N. Cooper, and F. Latif
Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Cancer Res., May 1, 2005; 65(9): 3497 - 3508.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. M. Whang, Y. H. Kim, J. S. Kim, and Y. D. Yoo
RASSF1A Suppresses the c-Jun-NH2-Kinase Pathway and Inhibits Cell Cycle Progression
Cancer Res., May 1, 2005; 65(9): 3682 - 3690.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Tommasi, R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer
Tumor Susceptibility of Rassf1a Knockout Mice
Cancer Res., January 1, 2005; 65(1): 92 - 98.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. H. N. Wong, J. Chan, J. Wong, and P. K. H. Tam
Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1
Clin. Cancer Res., February 1, 2004; 10(3): 994 - 1002.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. L. Fenton, A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J. D. Minna, J. Downward, et al.
Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene
Cancer Res., January 1, 2004; 64(1): 102 - 107.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Akiyama, C. Maesawa, S. Ogasawara, M. Terashima, and T. Masuda
Cell-Type-Specific Repression of the Maspin Gene Is Disrupted Frequently by Demethylation at the Promoter Region in Gastric Intestinal Metaplasia and Cancer Cells
Am. J. Pathol., November 1, 2003; 163(5): 1911 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al.
Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma
Cancer Res., September 1, 2003; 63(17): 5344 - 5351.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Zhong, W. Yeo, M. W. Tang, N. Wong, P. B. S. Lai, and P. J. Johnson
Intensive Hypermethylation of the CpG Island of Ras Association Domain Family 1A in Hepatitis B Virus-associated Hepatocellular Carcinomas
Clin. Cancer Res., August 1, 2003; 9(9): 3376 - 3382.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. E. Lusher, J. C. Lindsey, F. Latif, A. D. J. Pearson, D. W. Ellison, and S. C. Clifford
Biallelic Epigenetic Inactivation of the RASSF1A Tumor Suppressor Gene in Medulloblastoma Development
Cancer Res., October 15, 2002; 62(20): 5906 - 5911.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Kuzmin, J. W. Gillespie, A. Protopopov, L. Geil, K. Dreijerink, Y. Yang, C. D. Vocke, F.-M. Duh, E. Zabarovsky, J. D. Minna, et al.
The RASSF1A Tumor Suppressor Gene Is Inactivated in Prostate Tumors and Suppresses Growth of Prostate Carcinoma Cells
Cancer Res., June 1, 2002; 62(12): 3498 - 3502.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.